In This Episode: FDA Turbulence & Regeneron’s Reset

This week’s video unpacks two major biotech stories. First, we break down the quiet but serious disruption at the FDA—budget cuts, staffing losses, and why the real impact may not be visible for months. Then, we dig into Regeneron’s sharp stock decline, EYLEA franchise erosion, and what it will take to reignite investor confidence. Execution—not promise…